Search research articles
Contact Us
Filters
Showing results (1-10 of 239) with videos related to
Page
of 24
Sort By:
Oncoscience
|
October 27, 2015
JAK-STAT in lymphoproliferative disorders
Raul Rabadan, Giorgio Inghirami
Current Opinion in Pharmacology
|
June 9, 2015
Anaplastic lymphoma kinase inhibitors
Ramona Crescenzo, Giorgio Inghirami
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 21, 2025
A sophisticated approach to targeting TERT activity in DLBCL
Giorgio Inghirami, Leandro Cerchietti
Current Opinion in Hematology
|
June 9, 2017
Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?
Marco Pizzi, Giorgio Inghirami
Seminars in Diagnostic Pathology
|
August 20, 2011
Anaplastic large-cell lymphoma
Giorgio Inghirami, Stefano A Pileri,
Blood
|
May 21, 2026
Can we target CTCL clonal evolution and improve outcomes?
Paul Dylan Barone, Giorgio Inghirami
Hematological Oncology
|
May 26, 2017
Are we ready to take full advantage of patient-derived tumor xenograft models?
Peter W Kyriakides, Giorgio Inghirami
Proceedings of the National Academy of Sciences of the United States of America
|
June 28, 2006
STAT3: a multifaceted oncogene
David E Levy, Giorgio Inghirami
Annual Review of Pathology
|
February 8, 2018
Pathogenesis of Peripheral T Cell Lymphoma
Marco Pizzi, Elizabeth Margolskee, Giorgio Inghirami
Advances in Experimental Medicine and Biology
|
August 19, 2007
Identification and validation of the anaplastic large cell lymphoma signature
Roberto Piva, Elisa Pellegrino, Giorgio Inghirami
Page
of 24
Search research articles
Search
Showing results (1-10 of 239) with videos related to
Sort By:
Page
of 24
Oncoscience
|
October 27, 2015
JAK-STAT in lymphoproliferative disorders
Raul Rabadan, Giorgio Inghirami
Current Opinion in Pharmacology
|
June 9, 2015
Anaplastic lymphoma kinase inhibitors
Ramona Crescenzo, Giorgio Inghirami
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
September 21, 2025
A sophisticated approach to targeting TERT activity in DLBCL
Giorgio Inghirami, Leandro Cerchietti
Current Opinion in Hematology
|
June 9, 2017
Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?
Marco Pizzi, Giorgio Inghirami
Seminars in Diagnostic Pathology
|
August 20, 2011
Anaplastic large-cell lymphoma
Giorgio Inghirami, Stefano A Pileri,
Blood
|
May 21, 2026
Can we target CTCL clonal evolution and improve outcomes?
Paul Dylan Barone, Giorgio Inghirami
Hematological Oncology
|
May 26, 2017
Are we ready to take full advantage of patient-derived tumor xenograft models?
Peter W Kyriakides, Giorgio Inghirami
Proceedings of the National Academy of Sciences of the United States of America
|
June 28, 2006
STAT3: a multifaceted oncogene
David E Levy, Giorgio Inghirami
Annual Review of Pathology
|
February 8, 2018
Pathogenesis of Peripheral T Cell Lymphoma
Marco Pizzi, Elizabeth Margolskee, Giorgio Inghirami
Advances in Experimental Medicine and Biology
|
August 19, 2007
Identification and validation of the anaplastic large cell lymphoma signature
Roberto Piva, Elisa Pellegrino, Giorgio Inghirami
Page
of 24